β-blockers in the treatment of hypertension: Are there clinically relevant differences?

Postgraduate Medicine

Volumn 121, Issue 3, 2009, Pages 90-98

  Weir, Matthew R ^a,b  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

blockers; Cardiovascular disease; Carvedilol; Combination therapy; Hypertension; Vasodilation

Indexed keywords

ACEBUTOLOL; ALDOSTERONE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ANGIOTENSIN; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LABETALOL; METOPROLOL; NADOLOL; NEBIVOLOL; NITRIC OXIDE; PENBUTOLOL; PINDOLOL; PROPRANOLOL; RENIN; TIMOLOL;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG CHOICE; FATIGUE; HEADACHE; HEART OUTPUT; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RHINOPHARYNGITIS; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; VASCULAR RESISTANCE; VASODILATATION; BLOOD PRESSURE; DRUG EFFECT; PHYSIOLOGY; REVIEW; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; TREATMENT OUTCOME; VASODILATION;

EID: 67549107139     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2009.05.2007     Document Type: Article

References (48)

1. Chobanian AV, Bakris GL, Black HR, et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 2003;42(6):1206-1252.
2. Rosamond W, Flegal K, Furie K, et al; American heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4):e25-e146.
3. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217- 223. (Pubitemid 40138015)
4. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25(3):305-313.
5. Williams GH. Approach to the patient with hypertension. In: Braunwald E, Kasper DL, Hauser SL, eds. Harrison's Principles of Internal Medicine. New York, NY: McGraw-Hill; 2001:211-213.
6. Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension. 1999;34(4 pt 2):724-728. (Pubitemid 29501288)
7. Guyton AC, Hall JE. Nervous regulation of the circulation and rapid control of arterial pressure. Textbook of Medical Physiology. Philadelphia, PA: W.B. Saunders Co; 2000:184-194.
8. Guyton AC, Hall JE. Dominant role of the kidney in long-term regulation of arterial pressure and in hypertension: the integrated system for pressure control. Textbook of Medical Physiology. Philadelphia, PA: W.B. Saunders, Co; 2000:195-209.
9. Egan BM, Basile J, Chilton RJ, Cohen JD. Cardioprotection: the role of beta-blocker therapy. J Chn Hypertsens (Greenwich). 2005;7(7):409-416.
10. Frishman WH. A historical perspective on the development of beta-adrenergic blockers. J Clin Hypertens. 2007;9:19-27.
11. Hoffman BB, Taylor P. Neurotransmission: the autonomic and somatic motor nervous systems. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw Hill; 2001.
12. Brodde OE, Bruck H, Leineweber K. Cardiac adrenoceptors: physiological and pathophysiological relevance. J Pharmacol Sci. 2006;100(5):323-337. (Pubitemid 44609527)
13. Hofman A, Boomsma F, Schalekamp MA, Valkenburg HA. Raised blood pressure and plasma noradrenaline concentrations in teenagers and young adults selected from an open population. Br Med J. 1979;1(6177):1536-1538. (Pubitemid 9221154)
14. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension. 1998;31(1):68-72. (Pubitemid 28124694)
15. Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension. 2004;43(4):699-706. (Pubitemid 38405571)
16. Kaplan NM. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, PA: W.B. Saunders Co; 1997.
17. Burns J, Sivananthan MU, Ball SG, Mackintosh AF, Mary DA, Greenwood JP. Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation. 2007;115(15):1999-2005. (Pubitemid 46625950)
18. Strand AH, Gudmundsdottir H, Os I, et al. Arterial plasma noradrenaline predicts left ventricular mass independently of blood pressure and body build in men who develop hypertension over 20 years. J Hypertens. 2006;24(5):905-913. (Pubitemid 43670462)
19. Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis. 1998;41(1 suppl 1):39-52. (Pubitemid 28381714)
20. Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol. 2007;50(7):563-572. (Pubitemid 47202065)
21. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ. 2006;174(12):1737-1742. (Pubitemid 43893565)
22. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366(9496):1545-1553. (Pubitemid 41540112)
23. Lopez-Sendon J, Swedberg K, McMurray J, et al; Task Force on Beta-Blockers of the European Society of Cardiology. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 2004;25(15):1341-1362.
24. Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers. Curr Hypertens Rep. 2007;9(4):269-277. (Pubitemid 47377026)
25. Blumenfeld JD, Sealey JE, Mann SJ, et al. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin- aldosterone system in normotensive and hypertensive subjects. Am J Hypertens. 1999;12(5):451-459. (Pubitemid 29238406)
26. Cambridge D, Whiting MV, Butterfield LJ, Allan G. The effects of combined angiotensin converting enzyme inhibition and beta-adrenoceptor blockade on plasma renin activity in anaesthetized dogs. Br J Pharmacol. 1992;106(2):342-347.
27. Messerli FH, Grossman E. Beta-Blockers in hypertension: is carvedilol different? Am J Cardiol. 2004;93(9A):7B-12B.
28. Bakris GL, Fonseca V, Katholi RE, et al; GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292(18):2227-2236.
29. Messerli FH, Bell DS, Fonseca V, et al; GEMINI Investigators. Body weight changes with beta-blocker use: results from GEMINI. Am J Med. 2007;120(7):610-615.
30. Marchi F, Ciriello G. Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol. Adv Ther. 1995;12(4):212-221.
31. Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs. 2007;67(8):1097-1107. (Pubitemid 46871021)
32. Kanto JH. Current status of labetalol, the first alpha- and beta-blocking agent. Int J Clin Pharmacol Ther Toxicol. 1985;23(11):617-628. (Pubitemid 16250305)
33. Novo S, Abrignani MG, Sapienza ND, et al. Partial regression of vascular structural alterations in hypertensive patients treated with alpha-beta-blocker, labetalol. Int Angiol. 1992;11(2):137-141.
34. Abernethy DR, Bartos P, Plachetka JR. Labetalol in the treatment of hypertension in elderly and younger patients. J Clin Pharmacol. 1987;27(11):902-906. (Pubitemid 18259031)
35. Flamenbaum W, Weber MA, McMahon FG, Materson BJ, Carr AA, Poland M. Monotherapy with labetalol compared with propranolol. Differential effects by race. J Clin Hypertens. 1985;1(1):56-69.
36. VHA Pharmacy Benefits Management Services, Medical Advisory Panel. National PBM Drug Monograph Nebivolol (Bystolic®). pbm.va.gov/monograph/ Nebivolol.doc. 2008.
37. Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol. 2003;92(3):344-348. (Pubitemid 36897730)
38. Weiss R. Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation. Vasc Health Risk Manag. 2006;2(3):303-308. (Pubitemid 44275465)
39. Weiss RJ, Weber MA, Carr AA, Sullivan WA. A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension. J Clin Hypertens (Greenwich). 2007;9(9):667-676.
40. Afonso RA, Patarrao RS, Macedo MP, Carmo MM. Carvedilol action is dependent on endogenous production of nitric oxide. Am J Hypertens. 2006;19(4):419-425.
41. Kozlovski VI, Lomnicka M, Chlopicki S. Nebivovol and carvedilol induce NO-dependent coronary vasodilatation that is unlikely to be mediated by extracellular ATP in the isolated guinea pig heart. Pharmacol Rep. 2006;58(suppl):103-110.
42. Weber K, Bohmeke T, van der Does R, Taylor SH. Hemodynamic differences between metoprolol and carvedilol in hypertensive patients. Am J Hypertens. 1998;11(5):614-617. (Pubitemid 28270726)
43. Weber MA, Bakris GL, Tarka EA, Iyengar M, Fleck R, Sica DA. Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. J Clin Hypertens (Greenwich). 2006;8(12):840-849.
44. Weber MA, Sica DA, Tarka EA, Iyengar M, Fleck R, Bakris GL. Controlled-release carvedilol in the treatment of essential hypertension. Am J Cardiol. 2006;98(7A):32L-38L. (Pubitemid 44488584)
45. Fonarow GC. Profile of carvedilol controlled-release: a new once-daily formulation of carvedilol. Expert Opin Pharmacother. 2006;7(18):2533-2546. (Pubitemid 44932456)
46. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997.
47. Weir MR. Risk-based classification of hypertension and the role of combination therapy. J Clin Hypertens (Greenwich). 2008;10(1 suppl 1):4-12.
48. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427. (Pubitemid 36776153)